STOCK TITAN

PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ: PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time.

In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accessed by using the link below.

Earnings Call Webcast - CLICK HERE

A replay of the earnings conference call will be available for 30 days beginning approximately one hour after the conclusion of the call and can be found by visiting PolarityTE's website at https://www.polarityte.com/news-media/events, or by clicking on the link above.

About PolarityTE®

PolarityTE, Inc., headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative tissue products. PolarityTE's first regenerative tissue product is SkinTE®. PolarityTE has an open investigational new drug application (IND) for SkinTE® with the U.S. Food and Drug Administration (FDA) and is now pursuing the first of two pivotal studies on SkinTE® needed to support a biologics license application (BLA) for a chronic cutaneous ulcer indication. SkinTE® is available for investigational use only. Learn more at www.PolarityTE.com.

POLARITYTE, the POLARITYTE logo, SKINTE, and WHERE SELF REGENERATES SELF are registered trademarks of PolarityTE, Inc.

CONTACTS

Investors:
PolarityTE Investor Relations
ir@PolarityTE.com
(385) 831-5284

Media:
David Schull or Ignacio Guerrero-Ros
David.schull@russopartnersllc.com 
Ignacio.guerrero-ros@russopartnersllc.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/polarityte-to-report-q2-2022-financial-results-on-august-11-2022-301596394.html

SOURCE PolarityTE, Inc.

PTE

NASDAQ:PTE

PTE Rankings

PTE Latest News

PTE Stock Data

1.78M
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Salt Lake City

About PTE

polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients'​ own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™